SMARCA4-deficient lung and ovarian cancer cells show increased sensitivity to the KDM6 inhibitor GSK-J4, which can be an effective treatment option after cisplatin resistance (32). This evidence concerns the gene SMARCA4 and ovarian carcinoma.